Ronald Fellman is an Ophthalmology physician affiliated with University of North Texas at Dallas. OpenAlex indexes 131 publications with 3,529 citations (h-index 29); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
10740 N Central Expy
Suite 300
Dallas, TX 752312161
Telephone
214-360-0000Registry record last updated 1 Oct 2011.
Clinical trials
- Surgical Treatment of Refractory Open Angle Glaucoma
Sponsor: iScience Interventional Corporation
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202511 payments
- Amgen Inc.Program year20252 payments
- Johnson & Johnson Surgical Vision, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
77.9%Prostaglandin Analog29.7%Latanoprost83%Lumigan9%Travoprost4%Tafluprost2%Travatan Z1%Part D<11 patientsCarbonic Anhydrase Inhibitor21.8%Dorzolamide-Timolol62%Dorzolamide Hcl20%Acetazolamide6%Brinzolamide5%Simbrinza4%Azopt2%Part D<11 patients+ 9 more classes in this area
Cardiovascular
15.6%Beta blocker15.6%Timolol Maleate94%Betimol3%Carteolol Hcl3%Part D<11 patientsNervous system
2.8%Cholinergic Receptor Agonist2.8%Pilocarpine Hcl100%Part D≥43 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The Canonical Wnt Signaling Pathway Inhibits the Glucocorticoid Receptor Signaling Pathway in the Trabecular Meshwork
American Journal Of Pathology
2021 - Vision-Targeted Health-Related Quality-of-Life Survey for Evaluating Minimally Invasive Glaucoma Surgery
American Journal of Ophthalmology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Ali Bijani
Babol University of Medical Sciences
Hamid Asayesh
Ayatollah Boroujerdi University
John J. Huang
Isfahan University of Medical Sciences
Fotis Topouzis
National University of Singapore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”